US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Tourmaline Bio, Inc. - Common Stock (NQ:TRML)

47.98 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tourmaline Bio, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated (NYSE - CMA), Veeco Instruments Inc. (Nasdaq - VECO), Tourmaline Bio, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRML, CCRD, PBBK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates FSFG, ARIS, TRML on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated (NYSE - CMA), Veeco Instruments Inc. (Nasdaq - VECO), Tourmaline Bio, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WOW, PRO, TRML, PGRE on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: PROS Holdings, Inc. (NYSE – PROS), Paramount Group, Inc. (NYSE – PGRE), Tourmaline Bio, Inc. (Nasdaq - TRML), WideOpenWest, Inc. (NYSE - WOW)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PGRE, WOW, TRML, BTBD on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paramount Group, Inc. (NYSE – PGRE), Tourmaline Bio, Inc. (Nasdaq - TRML), BT Brands, Inc. (Nasdaq - BTBD), WideOpenWest, Inc. (NYSE - WOW)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRML, WOW, BTBD, WKHS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Tourmaline Bio, Inc. (Nasdaq - TRML), BT Brands, Inc. (Nasdaq - BTBD), WideOpenWest, Inc. (NYSE - WOW), Workhorse Group Inc. (Nasdaq - WKHS)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders
From The Ademi Firm
Via Business Wire
News headline image
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
News headline image
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >